Bachy E et al. Final analysis of the Ro-CHOP phase III study (conducted by LYSA): Romidepsin plus CHOP in patients with peripheral T-cell lymphoma. ASH 2020;Abstract 39.
Belada D et al. A phase 1b, open-label, randomized study to assess safety and preliminary efficacy of tafasitamab (MOR208) or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma: Analysis of the safety run-in phase. ASH 2020;Abstract 3028.
Gritti G et al. Polatuzumab vedotin plus venetoclax with rituximab in relapsed/refractory diffuse large B-cell lymphoma: Primary efficacy analysis of a phase Ib/II study. ASH 2020;Abstract 599.
Herrera A et al. Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma. ASH 2020;Abstract 472.
Horwitz S et al. The Echelon-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and chp (A + CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma. ASH 2020;Abstract 1150.
Hutchings M et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. ASH 2020;Abstract 403.
Hutchings M et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes including patients with prior CAR-T therapy: Updated dose escalation data epcoritamab demonstrates a consistent and favorable safety profile, with no grade ≥3 CRS events and limited neurotoxicity, in support of outpatient. ASH 2020;Abstract 402.
Jaeger U et al. Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) treated with tisagenlecleucel in the JULIET trial. ASH 2020;Abstract 1194.
Maddocks K et al. Long-term subgroup analyses from L-MIND, a phase 2 study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. ASH 2020;Abstract 3021.
Maerevoet M et al. Effect of age on the efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A post-hoc analysis from the SADAL pivotal study. ASH 2020;Abstract 1201.
Maloney D et al. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) vs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel in relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). ASH 2020;Abstract 2116.
Mehta A et al. Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor (CITADEL-205). ASH 2020;Abstract 1121.
Neelapu S et al. Interim analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients (pts) with high-risk large b cell lymphoma (LBCL). ASH 2020;Abstract 405.
Olszewski A et al. Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B cell lymphoma. ASH 2020;Abstract 401.
Palomba M et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in TRANSCEND NHL 001. ASH 2020;Abstract 118.
Puckrin R et al. Lack of effectiveness of intravenous high-dose methotrexate for prevention of CNS relapse in patients with high-risk DLBCL: A retrospective analysis from Alberta, Canada. ASH 2020;Abstract 477.
Ruan J et al. Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL). ASH 2020;Abstract 40.
Seymour E et al. Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: Results of a phase 1b study. ASH 2020;Abstract 2109.
Straus D et al. Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study. ASH 2020;Abstract 2973.
Tam CS et al. Ibrutinib plus venetoclax in patients with relapsed/refractory mantle cell lymphoma: Results from the safety run-in period of the phase 3 SYMPATICO study. ASH 2020;Abstract 2938.
Wang M et al. Acalabrutinib monotherapy in patients with relapsed/refractory MCL: Long-term efficacy and safety results from a phase 2 study. ASH 2020;Abstract 2040.
Wang M et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenström’s macroglobulinemia, and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study. ASH 2020;Abstract 117.
Wang M et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma. ASH 2020;Abstract 1120.
Yasenchak C et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. ASH 2020;Abstract 471.